SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…
Apriori to leverage foundational insights from the Crick's Legacy Study to further validate Octavia™ platform's ability to predict viral evolution…
Acquisition Poised to Drive Substantial Shareholder Value Through Innovative Technologies, Projected Multi-Million Revenues, and Strategic Leadership Alignment: Amin Janmohamed Steps…
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…
COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered…
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients…
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company…
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –SAN…
- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025…
Second Quarter Net Sales Increased 2.4% to $16.7 Million, Compared to $16.3 Million for the Second Quarter of 2024Net sales…